Impact of direct-acting antivirals for hepatitis C virus therapy on tacrolimus dosing in liver transplant recipients.
Alexandra L BixbyLinda FitzgeraldRachael LeekJessica MellingerPratima SharmaSarah TischerPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
From the start of treatment to 12 weeks post-DAA therapy, liver transplant recipients experienced a significant decrease in dose-normalized tacrolimus concentrations. In conclusion, close monitoring of tacrolimus concentrations is warranted during and following treatment with DAAs, as dose increases may be indicated in order to maintain therapeutic concentrations to prevent graft rejection.